Victory Capital Management Inc. Sells 2,505 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Victory Capital Management Inc. decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 131,353 shares of the biotechnology company's stock after selling 2,505 shares during the period. Victory Capital Management Inc. owned about 0.22% of Ascendis Pharma A/S worth $18,083,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $30,000. Jones Financial Companies Lllp boosted its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. grew its stake in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares during the last quarter. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the third quarter worth about $60,000. Finally, GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares during the period.

Analyst Ratings Changes

ASND has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 25th. TD Cowen reduced their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. Stifel Nicolaus upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Finally, Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $202.36.

Remove Ads

Ascendis Pharma A/S Stock Up 5.4 %

Shares of ASND opened at $145.63 on Wednesday. The stock has a market cap of $8.84 billion, a P/E ratio of -20.51 and a beta of 0.62. The business's 50 day moving average price is $137.52 and its 200-day moving average price is $134.41. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $158.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, equities analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.